1. Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far

   • Upinder Kaur
   • Bhairav Kumar Pathak
   • Sankha Shubhra Chakrabarti

   Review Article 09 March 2024 Pages: 223 - 250

   

2. An Open-Label Study to Assess Monthly Risperidone Injections (180 mg) Following Switch from Daily Oral Risperidone (6 mg) in Stable Schizophrenic Patients

   • David P. Walling
   • Sunita N. Shinde
   • Celine M. Laffont

   Original Research Article Open access 22 February 2024 Pages: 251 - 260

   

3. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan

   • Teppei Hagino
   • Risa Hamada
   • Naoko Kanda

   Original Research Article 06 March 2024 Pages: 261 - 269

   

4. Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)

   • Xi Tan
   • Victoria Divino
   • Aaron A. King

   Original Research Article Open access 20 March 2024 Pages: 271 - 284

   

5. Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis

   • María Chaparro
   • Daniel Ceballos
   • Javier P. Gisbert

   Research Letter Open access 19 March 2024 Pages: 285 - 288

6. Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study

   • Gianni Carraro
   • Valentina Di Vico
   • Lorenzo A. Calò

   Research Letter 02 March 2024 Pages: 289 - 291